Kodiak Sciences Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Kodiak Sciences Inc 公司

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Kodiak Sciences Inc簡介



公司代碼KOD

公司名稱Kodiak Sciences Inc

上市日期Oct 04, 2018

CEOPerlroth (Victor)

員工數量109

證券類型Ordinary Share

年結日Oct 04

公司地址1250 Page Mill Rd

城市PALO ALTO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94304

電話16502810850

網址https://kodiak.com/

公司代碼KOD

上市日期Oct 04, 2018

CEOPerlroth (Victor)

Kodiak Sciences Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

183.32K

+1152.00%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

--

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

--

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

--

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Felix J. Baker, Ph.D.

Independent Director

--

Dr. Bassil I. Dahiyat, Ph.D.

Independent Director

--

Dr. Taiyin Yang, Ph.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

183.32K

+1152.00%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

--

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

--

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

--

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Felix J. Baker, Ph.D.

Independent Director

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 2月8日週日

持股股東

股東類型

持股股東

佔比

Baker Bros. Advisors LP

32.66%

Point72 Asset Management, L.P.

4.65%

Perlroth (Victor D)

4.42%

BlackRock Institutional Trust Company, N.A.

3.93%

The Vanguard Group, Inc.

3.79%

其他

50.55%

持股股東

佔比

Baker Bros. Advisors LP

32.66%

Point72 Asset Management, L.P.

4.65%

Perlroth (Victor D)

4.42%

BlackRock Institutional Trust Company, N.A.

3.93%

The Vanguard Group, Inc.

3.79%

其他

50.55%

股東類型

持股股東

佔比

Hedge Fund

46.25%

Investment Advisor

19.99%

Investment Advisor/Hedge Fund

9.35%

Individual Investor

4.78%

Research Firm

1.78%

Endowment Fund

1.13%

Private Equity

1.04%

Pension Fund

0.17%

Sovereign Wealth Fund

0.08%

其他

15.43%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

265

48.79M

79.98%

+1.64M

2025Q3

248

41.93M

79.39%

-9.11M

2025Q2

273

46.04M

87.25%

-8.67M

2025Q1

302

46.32M

87.78%

-8.84M

2024Q4

308

44.88M

85.29%

-7.98M

2024Q3

318

42.74M

81.24%

-12.36M

2024Q2

326

43.49M

82.78%

-12.58M

2024Q1

345

46.64M

88.83%

-7.18M

2023Q4

377

44.39M

84.60%

-13.12M

2023Q3

391

45.97M

87.64%

-8.18M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Baker Bros. Advisors LP

19.92M

32.66%

+2.61M

+15.07%

Dec 18, 2025

Point72 Asset Management, L.P.

2.84M

4.65%

+2.38M

+526.72%

Sep 30, 2025

Perlroth (Victor D)

2.70M

4.42%

+527.00K

+24.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

2.40M

3.93%

-286.86K

-10.68%

Sep 30, 2025

The Vanguard Group, Inc.

1.95M

3.2%

+127.99K

+7.02%

Sep 30, 2025

Adage Capital Management, L.P.

1.33M

2.19%

-720.71K

-35.06%

Sep 30, 2025

ICONIQ Capital, LLC

1.27M

2.08%

--

Sep 30, 2025

TCG Crossover Management, LLC

1.15M

1.88%

--

Sep 30, 2025

SilverArc Capital Management, LLC

1.00M

1.64%

+598.46K

+149.04%

Sep 30, 2025

Acadian Asset Management LLC

969.91K

1.59%

-999.97K

-50.76%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Fidelity Enhanced Small Cap ETF

0.18%

iShares Micro-Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.11%

Invesco RAFI US 1500 Small-Mid ETF

0.06%

iShares Health Innovation Active ETF

0.06%

iShares Russell 2000 Value ETF

0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

0.05%

ProShares Hedge Replication ETF

0.03%

ProShares UltraPro Russell2000

0.03%

Proshares Ultra Russell 2000

0.02%

Fidelity Enhanced Small Cap ETF

佔比0.18%

iShares Micro-Cap ETF

佔比0.11%

Vanguard US Momentum Factor ETF

佔比0.11%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.06%

iShares Health Innovation Active ETF

佔比0.06%

iShares Russell 2000 Value ETF

佔比0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

佔比0.05%

ProShares Hedge Replication ETF

佔比0.03%

ProShares UltraPro Russell2000

佔比0.03%

Proshares Ultra Russell 2000

佔比0.02%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據